Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 plus low-dose steroids for pemphigus and pemphigoid
ChiCTR2500099202Phase 4Completed
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Mar 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of aldesleukin in pemphigus and pemphigoid (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Time to disease control. Started Mar 2025; status: completed.
02
Drugs
aldesleukin
03
Conditions
pemphiguspemphigoid
Beyond the preview
Go deeper on ChiCTR2500099202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099202.